Request for Proposal: Market Managers for
Tuberculosis Treatment and Diagnostics
Opens: March 16, 2015
Submission Deadline: April 24, 2015
Overview
Introduction
The Bill & Melinda Gates Foundation (the “Foundation”), through this Request for Proposals (RFP), invites initial
proposals (“Concepts”) from qualified organizations (“Applicants”) interested in receiving grant support to take on the
role(s) of a Market Manager for Tuberculosis Treatment and Diagnostics for priority treatment and diagnostic products;
and to facilitate the launch and sustained uptake of these products to reach those in need in high-burden countries such
as China, India and South Africa. From the submitted Concepts, one or more Applicants will be invited to submit a full
proposal, from which one will be competitively selected to receive a final grant award.
Background
The uptake and coverage rates of treatment and diagnostic products for tuberculosis (TB) are part of a broader pattern
that has become common in global health. Historically, global health interventions have seen low and slow uptake
despite both technological superiority and burden of disease. Other examples include anti-retrovirals (ARVs) for HIV
treatment, artemisinin combination therapies (ACTs) for malaria, amoxicillin dispersible tablets for childhood pneumonia,
and oral rehydration salts (ORS) for diarrhea—all technically superior products that took more than 15 years to achieve
only modest coverage rates. In order to ensure that diagnosis and treatment products reach developing countries and
their citizens, new strategies are needed.
Tuberculosis is one of the leading causes of death worldwide, and that burden has fallen disproportionately on the poor
and developing country citizens. An estimated 8.6 million new TB cases were reported in 2012, along with 1.3 million
deaths from the disease. Of all TB cases, it is estimated that only 68% are diagnosed before the patient develops active
TB, putting them at risk for infecting others and further spreading the disease. Once a global disease, the vast majority
of TB cases are now in the developing world, and in particular among the poorest and most disadvantaged in those
countries. There is also a significant population of TB sufferers who are co-infected with other illnesses such as HIV.
Although excellent testing and treatment options are available for most forms of TB, many people are not diagnosed
using the latest technology and therefore are not getting effective treatment services. In recent years, TB control efforts
have taken on increased urgency due to the emergence of multidrug-resistant TB (MDR-TB), a form of the disease that
is resistant to frontline drugs, and extensively drug-resistant TB (XDR-TB), which is also resistant to some second-line
drugs. It is estimated that there were hundreds of thousands of new cases of drug resistant TB in 2013, with that number
expected to climb. MDR TB is identified and treated with even less success than traditional TB, with it estimated that
less than half of cases are identified, and only around two thirds of those treated with appropriate drugs. New
approaches are needed in order to ensure that everyone in need of TB drugs, or a reliable way to get testing, has
access to care.
The Foundation’s TB strategy addresses many of the factors associated with the TB epidemic. The combined
deployment of vaccines, diagnostics, and drugs is essential to addressing the epidemic. As part of the TB strategy, the
Foundation is focusing on the development of shorter, simpler treatment regimens. Patients who do not complete their
treatment as prescribed are likely to continue to transmit TB to others and may develop drug-resistant strains that can
take up to two years to treat with more expensive, second-line drugs. The TB strategy has a strong country focus, with
China, India and South Africa being the initial priority countries.
In recent years, TB control efforts have reduced the number of deaths from the disease as well as incidences of new
infections. After nearly 40 years of stasis, there have been huge advances in both first and second line treatments,
beginning with bedaquiline, and with a range of other promising treatments in the pipeline. For diagnostics, the recent
introduction of GeneXpert has greatly improved the ability to match potential TB illness to appropriate treatment.
Page 1 of 8
© 2014 Bill & Melinda Gates Foundation
Market Managers for TB Treatment and Diagnostics:
However, there are concerns that technological advances alone will not curb the spread of TB. To date, the Foundation
has not seen uptake and coverage rates to match these advances, resulting in millions of people in developing countries
unaware of their condition, or on sub-optimal or no treatment for the disease. Transformative technologies, such as
GeneXpert, have been slow to roll out to high burden countries, resulting in thousands of missed opportunities for
appropriate TB care. Potentially game-changing pipeline drugs, such as PaMZ, currently have no diagnostic that has the
assay necessary to correctly determine whether a patient should be put on it. Lack of coordination, inefficiencies in data
collection and information sharing, and a product—rather than portfolio—focus are just a few of the reasons that
coverage has not been achieved. The coverage of diagnostic and treatment products will also need to improve
dramatically in order to reach current targets.
Goal
The purpose of this RFP is to solicit Concepts from qualified organizations seeking support to take on the role of Market
Manager for Tuberculosis Treatment and Diagnostics as a way to accelerate access to diagnosis and care for people
with or at risk of contracting or spreading TB. In general terms, a Market Manager is an entity, likely a team within a
larger organization, which has responsibility, ability and accountability to plan, coordinate, and execute critical path
activities in partnership with manufacturers and other stakeholders in order to drive effective coverage of interventions.
Market Managers will perform three main functions to drive uptake: coordinate and share market insights and analytics;
assist with overall strategy setting; and provide portfolio-level delivery capacity in collaboration with manufacturing
partners. The success of any grant made under this RFP will be judged based upon the Market Manager’s success in
hitting targets developed together with the Foundation for uptake of priority products within a particular therapeutic area.
The Foundation is also considering a pay-for-performance scheme that would reward grantees for exceeding coverage
targets, and will explore this idea further with any Applicants invited to develop a full proposal.
Scope and Approach
The Market Manager role is the result of a comprehensive analysis of the root causes leading to the slow introduction
and low uptake of many technically superior and critical devices, drugs and diagnostics. Slow introduction and low
uptake can be caused by many factors, but some of the most common in developing country health markets are
inappropriate product design, inefficient launch of planning and execution, and reliance on systems that do not rapidly
accommodate innovation. Other causes can include technology designs that are not optimized for market impact;
partners playing outside their strengths/comfort zones; and having different partners engage at different stages of the
development process, leading to lack of knowledge transfer. Although there are many symptoms, the root causes are
often fundamental inefficiencies for product adoption in resource-limited settings.
The following describes services or roles where a Market Manager could add value. The actual role of the Market
Manager will depend on the specific treatment area, as well as their pipeline and focus countries.


Page 2 of 8
Market Oversight & Coordination (required) – This is the essential role on which other services depend.
Potential activities are listed below, but Applicants are strongly encouraged to propose targets based on
outcomes/increased coverage rather than inputs/activities. The role described below can also add value for
interventions already existing in the market.
o Assessing current market state: Coverage/market share of relevant intervention(s);
regulatory/registration pathways for pipeline products; global and country policy guidance; assessment
of political will and country capacity for implementation in target countries; financial forecasting including
both probable commitment of country resources and projections of manufacturing costs; medium-term
demand; product pipeline; current and future predicted market prices; and supply capacity;
o Developing and coordinating delivery activities: Identifies actors (e.g. suppliers, global agencies,
implementers, etc.) responsible to drive coverage; works together with stakeholders to clarify roles and
responsibilities; coordinates activities across actors; and tracks the progress of various stakeholders
against agreed-upon roles and targets;
o Tracking and reporting progress: Tracking trends in coverage/use across public and private markets and
ensuring provider/user feedback is translated into next generation products;
o Troubleshooting: Identifies when activities are off-track or bottlenecks emerge and flexes to address
problem - either by managing directly or by assigning responsibility to a better placed actor;
o Communications: Being a go-to resource on issue and sharing progress transparently.
Go-to-Market Strategic Planning – Planning operational activities to drive roll-out and assign
roles/responsibilities to execute (primarily in countries with product adoption) including:
o Building evidence to accelerate global and country policy-making decisions;
© 2014 Bill & Melinda Gates Foundation
Market Managers for TB Treatment and Diagnostics:
o







Identifying first wave countries and building launch plans/operational research/financing strategies/etc.
to pave the way;
o Ensuring timely registration and inclusion in procurement tenders;
o Facilitating an appropriate ecosystem for impact, including ensuring technical guidance in place, training
programs are developed and active and stakeholders are prepared to adopt the intervention; etc.
o Acting as a commercial partner with product developers – actual service delivery may be implemented
by others.
Market Research/Insights – Leveraging knowledge from partners across countries (developed via its Market
Oversight & Coordination role) to advise product development and design/Target Product Profile (TPP)
decisions.
Pre-launch Market Testing – The same network aforementioned could also be leveraged to test products with
later design lock-in (e.g. diagnostics), brainstorm program designs, and assess acceptability among key opinion
leaders/stakeholders/users.
Manufacturing Strategy Support – Translating demand forecasts to inform manufacturing strategies.
Regulatory Strategy Support – Where there are multiple products being managed by different development
partners over time, ensure lessons are transferred from one candidate to the next in pursuing quality assurance.
In-country Registration Support – Where either the registration pathway is not clear or the manufacturer lacks
interest to register in certain geographies, identify local partners to facilitate registration (as often depends upon
local networks).
Market Intelligence and Market Dynamics – Monitor global trends in the marketplace to proactively identify
challenges in market economics and bring in market dynamic partners to address challenges in pricing,
forecasting and supplier capacity.
Market Implementation Knowledge Sharing – Once a product is launched, take lessons and tools from
increasing coverage in one country and share with partners in other geographies, as well as across products.
Potential Market Manager Roles across Product Development Lifecycle
The Market Manager is designed to respond to this need for the kind of consolidated oversight and close partnership
that can address many of these challenges. Often, delivery strategies are based around products, not portfolios,
resulting in duplication, competition and/or lack of coordination among complementary products. This fragments
activities among actors and products, rather than facilitating coordination, collaboration and ownership over a portfolio of
related products. For example, there is currently a lack of an efficient means to gain market insights from different but
related products early and use these to inform the design, development and delivery of multiple products. Similarly, both
commercialization and deep country expertise are necessary to launch and grow a product in a target geography, but
more often than not the responsibility of different stages of product delivery are divided up between different partners,
resulting in duplicated effort and loss of valuable knowledge. The Market Manager would ideally provide a single
consistent delivery partner across the different stages of product development, ensuring information is updated, shared
and of a high quality.
Page 3 of 8
© 2014 Bill & Melinda Gates Foundation
Market Managers for TB Treatment and Diagnostics:
While it is important that a Market Manager have some capability in all of the above areas, the needs of different
therapeutic areas lend themselves to different capacities required. In the TB Treatment and Diagnostics space, the
critical gaps appear to be:
 Coordination and Ownership. The largest need is for a body to serve as both a coordinating mechanism among
different stakeholders. For TB treatment and diagnostics, in particular, the greatest need is for coordination
between the treatment and diagnostics players to ensure that complementary products are optimally launched.
The most promising pipeline drugs for drug sensitive patients currently has no accompanying diagnostic test,
and both the Foundation and our development partners see huge value in having a partner who can ensure that
drugs and their accompanying diagnostics are launched in coordination. There is also a need for an overall
steward of the space, who is able to work with and across stakeholders to recommend impartial, evidencebased decisions about the product development, launch and scale needed to track and achieve the ultimate
goal of increased TB treatment;

Market Intelligence that will help current partners to share information about product demand and combine and
streamline approaches to regulatory processes both globally and in-country, and ensure that any gaps are filled.
In particular, there appears to be a need coordinate and share strategic demand forecasting for new second-line
drugs and their accompanying diagnostics;

Delivery Planning support for new/pipeline drugs and diagnostics, including support for regulatory,
manufacturing, demand, local and global policy guidance, pricing strategy, etc. in target countries;

Linkage to Care support for partnerships and activities that will improve in linking diagnosis to treatment in
priority countries;

Scale Up and Coverage Tracking in the short and medium term at both the global and country level for
diagnostics products that are currently in the market.
The Foundation plans on working with the Market Manager grantee in the proposal and post-award phases to set
targets for priority products and countries, with the Market Manager in the lead. As per the response guidelines below,
the Foundation would like Applicants to include ideas on appropriate targets in their Concepts, as requested in the
Response Guidelines below. Representative targets for TB could include:



Increasing the percentage TB suspects diagnosed with a molecular diagnostic from baseline (1%) to 83% in
China, baseline (1%) to 27% in India, and baseline (72%) to 94% in South Africa by 2020;
Increasing the percentage of TB smear or GeneXpert positive patients that receive drug susceptibility testing
(with molecular diagnostic) from baseline (20%) to 75% in China and baseline (50%) to 67% in India, and
continue 100% coverage in South Africa by 2020;
Increasing the percentage of drug sensitive and drug resistant patients on novel PaMZ treatment from baseline
(0%) to 32% in China, baseline (0%) to 10% in India, and baseline (0%) to 30% in South Africa by 2022.
However, it is important to note that these lists are only indicative of the Foundation’s preliminary analysis in these
areas. The Foundation recognizes that its partners often have different knowledge based upon their experiences in the
field, and the Foundation encourages Applicants to respond to the Concept questions below based upon their own
knowledge of the different therapeutic areas and their markets. The Foundation also expects priorities to change over
time, and is looking for Applicants who have a clear outlook on the first year or two but who are willing to be flexible and
adaptable in the future in order to “do what it takes” to achieve coverage targets. Ultimately, the success of the Market
Manager grantee will be evaluated based upon reaching coverage outcomes, rather than completing activities or
process milestones.
The anticipated grant period is 5-7 years contingent on a successful mid-point evaluation, although Applicants are
welcome to suggest alternative grant periods in line with the proposed approach.
Rules & Guidelines
Eligibility
Funding Criteria
Page 4 of 8
© 2014 Bill & Melinda Gates Foundation
Market Managers for TB Treatment and Diagnostics:
The ideal Applicant for this work will have the following qualifications:












501(c)(3) organization status or certified international equivalent;
Success in meeting organizational and client goals;
Demonstrated expertise in the therapeutic area of TB, and knowledge of existing and pipeline products related
to the product areas addressed in its Concept;
Good relationships with key stakeholders in the TB space, including funders, procurers, regulatory bodies,
manufacturers/Product Development Partners, delivery agencies and suppliers;
Good relationships with ministries of health and relevant stakeholders in the priority countries of China, India
and South Africa;
Country-level presence, network or deep understanding of local context in China, India and South Africa;
Success building and maintaining relationships among different stakeholders with varied goals;
Be, and be perceived as, unbiased towards any particular TB product;
Demonstrated understanding of the nuances and complexities of the TB product landscape and delivery
challenges in high-burden countries;
Extensive experience with product commercialization and scale up, or demonstrated ability to manage and
conduct product commercialization via sub-contracts or partnerships;
The capacity to administer and manage sub-contracts as needed;
An organizational strategic vision and leadership support that includes expanding into the Market Manager
space.
Organizations receiving grants must to comply with Foundation requirements for submission of narrative and financial
reports in addition to periodic information needed for overall project performance monitoring and management.
This Concept is intended to solicit initial Concepts no longer than 10 pages responding to the questions laid out in the
submission guidelines from organizations with existing experience in both the therapeutic area of interest and in product
commercialization, as well as an organizational interest in growing into the Market Manager role beyond the period of
any awarded grant. This document is intended to gather responses to key questions from interested parties, after which
a small number of those parties will be invited to complete a full proposal.
Exclusion Criteria
Due to potential conflicts of interest, the Foundation is not soliciting Concepts from for-profit organizations or
organizations with a financial stake in particular in-market or pipeline TB products. The Foundation is also not accepting
concepts from unaffiliated individuals.
Due to the Foundation’s status as a public charity, proposals including work in countries under active OFAC sanctions
will not be considered for funding.
Evaluation Criteria
The Foundation’s relevant internal experts and external reviewers will evaluate submitted Concepts with regard to the
following criteria:










Overall approach; coherence and relevance of proposed work plan;
Capacity of the Applicant to deliver on the proposed objectives;
Relevant experience, including previous subject matter and geographic experience, as stated in the
Response Requirements below;
Relevant capacity and capabilities;
Reputation for completing similar work;
Connections with stakeholders in the TB space;
Organizational culture;
Estimated costs of the services;
Adherence to guidelines set forth in this document;
Additional evaluation criteria the Foundation considers relevant to the specific services in question.
The relative weighting and priority of these criteria will be at the Foundation’s discretion. The Foundation will share the
criteria and weighting with Applicants who are invited to submit a full proposal.
Page 5 of 8
© 2014 Bill & Melinda Gates Foundation
Market Managers for TB Treatment and Diagnostics:
Budget Expectations
Applicants should submit an estimated high-level budget that includes proposed spending in major cost categories and
an estimated project timeline. Budgets should be organized into the following cost categories: personnel; required travel;
consultants; capital equipment; other direct costs; and sub-awards (including sub-grants or sub-contracts). Applicants
whose Concepts are selected will be asked to submit a more fully developed budget in a standard Foundation format.
All budgets must be in compliance with the Foundation’s indirect cost policy:
http://www.gatesfoundation.org/grantseeker/Documents/Indirect_Cost_Policy.pdf.
Activities & Timeline
March 16, 2015: Request announced.
April 13, 2015 – 2:00PM (PST): Deadline for clarifying questions.
April 24, 2015 – 2:00PM (PST): Deadline for submitting Concepts.
June 5, 2015: Finalists notified, full proposals requested.
September 23, 2015 (anticipated): Awards announced.
How to Submit a Concept
Response Requirements
For the purpose of this RFP, the Foundation requests that the Applicants focus their Concepts on addressing the
following questions. Concepts should be no longer than 10 pages in length. The Foundation will then ask any Applicants
selected to move forward to develop a more detailed proposal that outlines their approach and budget more fully.
Questions for Applicants:
1. Why is your organization interested in taking on this role? How does it fit with the vision of your institution
moving forward?
2. What is your experience in this particular therapeutic area? What is your experience and your current
capacity/partnerships in China, India and South Africa?
3. Do you see any potential conflicts in playing this role given involvement in other projects or associations with
specific products?
4. When you look out over the next five years, what do you think will be the key issues this market manager will
need to address?
5. If you assume your organization acts as the Market Manager on the key issues outlined above, what would you
propose the Foundation hold you accountable for to demonstrate progress against the aforementioned issues?
And what are the type of activities you project will be necessary to achieve these results?
6. Would your organization consider a pay-for-performance model that covered operating costs but offered
bonuses for achieving additional coverage targets? If so, how might that be structured?
7. How would you approach picking additional target countries and what criteria might you use (for TB target
countries beyond the initial priorities of China, India and South Africa)?
8. What estimated resources (human and financial) do you think would be required to pursue the results and
activities listed in this RFP?
a. Regarding human resources – what type of people and skills do you think would be necessary? How
would you structure the team?
b. Regarding financial resources – what factors might increase or decrease the financial requirements?
9. What will be the key internal (i.e. organizational capacity/culture/structure) factors that enable an organization to
be successful or not in this role?
10. What will the organization need from the Foundation to play this role effectively?
11. What external factors are the biggest risks and with what potential implications (expectation-wise, financial,
other)?
12. Why do you think your organization is capable of playing the Market Manager role successfully? What unique
capabilities does your firm have that are relevant for this project?
Page 6 of 8
© 2014 Bill & Melinda Gates Foundation
Market Managers for TB Treatment and Diagnostics:
In addition to answering the above, Applicants should also include the following:
 Three references who can address at least one of the following about individuals who are likely to be in the
proposed team:
o How they have managed projects that have either struggled or failed
o How they have managed resources (human and financial)
o How they interact with key stakeholders (host governments, product developers, key policy makers)
 Proposed organizational structure of Applicant’s team and its place in the Applicant’s overall organization,
and/or of any partnership arrangements;
 Basic profiles of team members and key hires or relationships necessary to achieve success. Note that CVs are
not required;
 High-level budget that includes proposed spending in major cost categories such as professional fees, travel,
expenses, etc., and proposed, high-level project timeline.
Please adhere to the instructions when responding to this RFP. All questions must be answered completely in order for
Applicant to be considered for this RFP.
Submission Instructions
Please submit an electronic copy of your Concept response (no more than 10 pages in Microsoft Word or Adobe PDF
format) through the application portal for this RFP under Opportunities on gatesfoundation.org.
Help Contact(s)
All communication relating to the RFP, including questions and clarifications, should be submitted via email to the
Foundation at marketmanagers@gatesfoundation.org. Please do not contact individual Foundation employees regarding
this RFP, as that may be grounds for disqualification.
The Foundation team will respond to questions with four business days. All answers to content questions and
clarifications will be distributed to all Applicants.
More Information
FAQ
Who can participate? This is an open solicitation. However, due to potential conflicts of interest, the Foundation is not
soliciting proposals from for-profit organizations or organizations with a financial or reputational stake in particular in
market or pipeline TB products. We are also not accepting concepts from unaffiliated individuals. Employees of the
Foundation and their respective immediate families cannot participate.
Will I receive any compensation for submitting? You will not receive any compensation for your submission even if it
is used by the Foundation or third parties in any way.
Can I submit a Concept addressing more than one Market Manager role? Yes, the Foundation is open to receiving
Concepts combining any of the open calls for Market Managers. If your plan to address more than one area, indicate
this clearly in the Concept.
What will the Foundation do with my submission? The Foundation will review all submissions. The Foundation may
also share your submission, or ideas contained within it, with external reviewers involved in this RFP. With this in mind,
please ensure that any materials you provide under this solicitation are your own, and understand that the Foundation
and others will have a right to view your submission, upon delivery, for noncommercial purposes under the scope of this
RFP.
Key Terms & Conditions
A. Disclosure Notice
To help the Foundation with its review of RFP responses, the Foundation may disclose proposals, documents, communications, and associated
materials submitted to the Foundation in response to this RFP (collectively, “Submission Materials”) to its employees, contingent workers, consultants,
independent subject matter experts, and potential co-funders. Please carefully consider the information included in the Submission Materials. If you
(the “Applicant”) have any doubts about the wisdom of disclosure of confidential or proprietary information, the Foundation recommends you consult
with your legal counsel and take any steps you deem necessary to protect your intellectual property. You may wish to consider whether such
Page 7 of 8
© 2014 Bill & Melinda Gates Foundation
Market Managers for TB Treatment and Diagnostics:
information is critical for evaluating the submission or if more general, non-confidential information may be adequate as an alternative for these
purposes.
Notwithstanding the Applicants characterization of any information as being confidential, the Foundation the Foundation is under no obligation to treat
such information as confidential.
B. Disclaimer
This RFP is not an offer to contract or award grant funds. The Foundation assumes no responsibility for the Applicants cost to respond to this RFP. All
responses generated by this RFP become the property of the Foundation.
C. Release and Verification
In exchange for the opportunity to be awarded a grant or contract, the Applicant agrees that the Foundation may, in its sole discretion: (1) amend or
cancel the RFP, in whole or in part, at any time; (2) extend the deadline for submitting responses; (3) determine whether a response does or does not
substantially comply with the requirements of the RFP; (4) waive any minor irregularity, informality or nonconformance with the provisions or
procedures of the RFP; (5) issue multiple awards; (6) share responses generated by this RFP with Foundation staff, consultants, contingent workers,
subject matter experts, and potential co-funders; and (7) copy the responses.
Applicant agrees not to bring a legal challenge of any kind against the Foundation relating to the Foundation’s selection and award of a grant or
contract arising from this RFP.
Applicant represents that it has responded to the RFP with complete honesty and accuracy. If facts provided in Applicant’s response change,
Applicant will supplement its response in writing with any deletions, additions or changes within ten days of the changes. Applicant will do this, as
necessary, throughout the selection process. Applicant understands that any material misrepresentation, including omissions, may disqualify it from
consideration for a grant or contract award.
By responding to this RFP, you are representing: (i) that you have authority to bind the named Applicant to the terms and conditions set forth above,
without amendment; and (ii) that you agree to be bound by them.
D. Global Access and Intellectual Property
Intellectual property (IP) rights and the management of IP rights are likely to play an important role in achieving the goals of this project. To this end,
the Foundation requires that, even at this stage, all Applicants seriously consider their willingness to submit a response in compliance with the
Foundation’s response requirements, a portion of which may ask for certain information and intentions regarding intellectual property concerns and
Global Access. Specifically, the Foundation requires that;
You will conduct and manage the Project and the Funded Developments in a manner that ensures Global Access. Your Global Access commitments
will survive the term of the Agreement. “Funded Developments” means the products, services, processes, technologies, materials, software, data,
other innovations, and intellectual property resulting from the Project (including modifications, improvements, and further developments to Background
Technology). “Background Technology” means any and all products, services, processes, technologies, materials, software, data, or other innovations,
and intellectual property created by You or a third party prior to or outside of the Project used as part of the Project. “Global Access” means: (a) the
knowledge and information gained from the Project will be promptly and broadly disseminated; and (b) the Funded Developments will be made
available and accessible at an affordable price (i) to people most in need within developing countries, or (ii) in support of the U.S. educational system
and public libraries, as applicable to the Project.
The Foundation will be selecting Applicants based on the conclusion that their technologies and expertise will be most appropriate for the success of
this RFP.
As part of the Foundation’s review and evaluation of each response, the Foundation will conduct due diligence with respect to each Applicant’s ability
and commitment to manage intellectual property in a manner consistent with the stated scientific and charitable goals of the Foundation. Due diligence
activities may include inquiry into an Applicant’s:
1) Freedom to operate (FTO) and ability to freely use and acquire needed background technology;
2) Commitment to promote the utilization, commercialization and availability of Funded Developments for public benefit
The Foundation encourages you to include this information in your response.
About the Bill & Melinda Gates Foundation
Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. We
work with partner organizations worldwide to tackle critical problems in four program areas. Our Global Development Division works to help the world’s
poorest people lift themselves out of hunger and poverty. Our Global Health Division aims to harness advances in science and technology to save
lives in developing countries. Our United States Division works to improve U.S. high school and postsecondary education and support vulnerable
children and families in Washington State. And our Global Policy, Advocacy & Communications Division seeks to build strategic relationships and
promote policies that will help advance our work. Our approach to grantmaking emphasizes collaboration, innovation, risk-taking, and, most
importantly, results.
To learn more about the Foundation's work, visit www.gatesfoundation.org.
Page 8 of 8
© 2014 Bill & Melinda Gates Foundation
Market Managers for TB Treatment and Diagnostics: